Close Menu

Breaking News

The company said it anticipates $19.2 million in revenues for full-year 2019, which would miss the consensus Wall Street estimate of $19.4 million.

The company recently changed its name from Interpace Diagnostics as it expands its focus to include drug discovery and development services.

Though the firm's top-line figures fell just shy of analysts' estimates, its installed base of ePlex analyzers grew 49 percent year over year.

Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.

Revenues of $850.5 million beat the company's prior revenue guidance, as well as the consensus Wall Street estimate.

Invitae estimated that in 2020 it would accession more than 725,000 samples and bring in more than $330 million in revenue, slightly above current Wall Street projections.

Total revenues of $36.6 million include product and service revenues, which are expected to be about $33.6 million and would be a 42 percent increase year over year.

The company also said that preliminary full-year 2019 revenues are expected to be up 6 percent, with sample-to-answer revenues up more than 20 percent.

Insight's portfolio includes a gene expression-based immuno-oncology assay for therapy response prediction.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.

The multistate rural health system will adopt Color technology to move to NGS and enhance online engagement for its Imagenetics clinical genomics program.

News items for the week of Jan. 6. 2020.

As part of the deal, Ionis also took a $10 million equity stake in Empirico and was the lead investor in the company's Series A-2 financing round.

Atreca will use Serimmune's Serum Epitope Repertoire Analysis (SERA) platform to identify the targets of anti-cancer antibodies Atreca is developing.

The group wants the agency to allow labs to discuss gene-drug relationships with "adequate evidence" in test reports and hold a public meeting.

The companies said the commercial partnership will help increase access to genomic information in the community oncology setting.

The AlloSeq cfDNA kit is used to quantify the level of donor-derived cell-free DNA in transplant recipients in order to measure graft health.

The new complaints add to related patent suits Illumina filed against BGI last year in the US, Germany, Switzerland, and Turkey.

The firm said it will use the funds to advance development of its HostDx immune response gene expression tests for acute infections and sepsis.

The oncology division of Human Longevity performs next-generation sequencing services for pharmaceutical customers and generated $10 million in revenue in 2019. 

The Church Lab spinout has now raised more than $50 million to develop and commercialize its fluorescent in situ sequencing technology for spatial genomics.

Quidel said that it expects fourth quarter 2019 revenues to be in the range of $151 million to $152 million, which would eclipse analyst expectations.

The firm also announced an exclusive distribution deal covering Israel for its T2 Resistance, T2Bacteria, and T2Candida panels

Pages

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.